{"corpus_id":43639036,"paper_sha":"7e3d964fb81a3192d5c11acc53f8cc48dfb369ec","doi":"10.1016/J.RMED.2005.09.020","arxiv_id":null,"pmid":16545951,"pmcid":null,"mag_id":2062041228,"dblp_id":null,"acl_id":null,"title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.","year":2006,"publication_date":"2006-07-01","venue":"Respiratory Medicine","journal":{"name":"Respiratory medicine","pages":"\n          1291-3\n        ","volume":"100 7"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","CaseReport"],"pubmed_pub_types":["Case Reports","Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":15,"citation_count":60,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Antibodies, Monoclonal","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D000911"},{"d":"Crohn Disease","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"}],"ui":"D003424"},{"d":"Gastrointestinal Agents","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D005765"},{"d":"Histoplasmosis","mj":false,"qs":[{"q":"chemically induced","mj":true,"ui":"Q000139"}],"ui":"D006660"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Infliximab","mj":false,"ui":"D000069285"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Opportunistic Infections","mj":false,"qs":[{"q":"chemically induced","mj":true,"ui":"Q000139"}],"ui":"D009894"},{"d":"Recurrence","mj":false,"ui":"D012008"},{"d":"Tumor Necrosis Factor-alpha","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"}],"ui":"D014409"}],"chemicals":[{"n":"Antibodies, Monoclonal","ui":"D000911","reg":"0"},{"n":"Gastrointestinal Agents","ui":"D005765","reg":"0"},{"n":"Tumor Necrosis Factor-alpha","ui":"D014409","reg":"0"},{"n":"Infliximab","ui":"D000069285","reg":"B72HH48FLU"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.resmedjournal.com/article/S0954611105003793/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/7e3d964fb81a3192d5c11acc53f8cc48dfb369ec","s2_open_access_license":"publisher-specific-oa","s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Histoplasma capsulatum (HC) is a thermally dimorphic ascomycete that is a significant cause of respiratory infections (>80%) in endemic areas (Midwest and southeast USA), but infections are rare in non-endemic areas. Most primary HC infections are subclinical or self-limited. While reactivation Histoplasmosis has been reported in the setting of immunosuppression, it remains unclear whether remote primary latent infection represents risk of endogenous reactivation after anti-tumor necrosis factor (TNF)-alpha therapy. We report a case of a patient who developed reactivation Histoplasmosis after receiving anti-TNF-alpha. To our knowledge, this is the first clear report of reactivation of \"latent\" Histoplasmosis after anti-TNF-alpha therapy.","claims":[{"public_id":"cl_2bb625102363259e1861af1e186e34ca","status":"active","text":"This is the first clear report of reactivation of latent Histoplasmosis after anti-TNF-alpha therapy.","confidence":0.95,"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/claims/cl_2bb625102363259e1861af1e186e34ca"}],"concepts":[{"public_id":"co_07f186ea6f395e944ff4c9687ccc1f2e","status":"active","name":"nonendemic area","description":"A geographic region where Histoplasma capsulatum infections are rare, in contrast to endemic areas like the Midwest and southeast USA.","types":["geographic region"],"aliases":["non-endemic area"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_07f186ea6f395e944ff4c9687ccc1f2e"},{"public_id":"co_16f9d6acd6f3d7ac0faa1e6785001376","status":"active","name":"reactivation histoplasmosis","description":"Histoplasmosis that arises from a prior latent infection after immunosuppression, as reported in this case following anti-TNF-alpha therapy.","types":["condition"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_16f9d6acd6f3d7ac0faa1e6785001376"},{"public_id":"co_6367c40b3676f8c42175fe06de894bca","status":"active","name":"Histoplasma capsulatum","description":"A thermally dimorphic ascomycete fungus that is a significant cause of respiratory infections in endemic areas.","types":["organism","pathogen"],"aliases":["HC"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_6367c40b3676f8c42175fe06de894bca"},{"public_id":"co_6c4ef4711cde86bc5e8f7b631eb6d241","status":"active","name":"anti-tumor necrosis factor alpha therapy","description":"A class of immunosuppressive biologic drugs that target TNF-alpha, implicated in reactivation of latent Histoplasmosis.","types":["therapeutic approach","drug class"],"aliases":["anti-TNF-alpha therapy"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_6c4ef4711cde86bc5e8f7b631eb6d241"},{"public_id":"co_99abba15e498ec9a18445a548373abc0","status":"active","name":"latent histoplasmosis","description":"A remote primary infection that remains asymptomatic or self-limited but may reactivate under immunosuppression.","types":["infection state"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_99abba15e498ec9a18445a548373abc0"}],"external_ids":{"DOI":"10.1016/J.RMED.2005.09.020","ArXiv":null,"PubMed":16545951,"PubMedCentral":null,"MAG":2062041228,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.resmedjournal.com/article/S0954611105003793/pdf","landing_url":"https://www.semanticscholar.org/paper/7e3d964fb81a3192d5c11acc53f8cc48dfb369ec","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"publisher-specific-oa","status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631386,"paper_uid":"9f5673ba-f74a-4234-a5b7-da2bf57d77a2","canonical_identity":{"paper_id":631386,"paper_uid":"9f5673ba-f74a-4234-a5b7-da2bf57d77a2","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/43639036"}